Clinical Scorecard: Enhancing Management of Brain Metastases Amidst Emerging Systemic Therapies: Insights from a Consecutive Series at a Single Institution

At a Glance

Key Highlights

• Systemic treatments including targeted molecular therapies and immunotherapy show variable intracranial efficacy depending on tumor and molecular characteristics.
• Multidisciplinary decision-making is essential to triage patients between immediate radiotherapy, delayed radiotherapy awaiting systemic treatment response, or best supportive care.
• Overall survival and treatment outcomes are influenced by factors such as primary tumor type, extracranial metastases status, Karnofsky Performance Score, and systemic treatment options.

Guideline-Based Recommendations

Diagnosis

• Include assessment of primary tumor type, molecular drivers (e.g., ALK, EGFR, PD-L1, BRAF), and extracranial metastases status.
• Use multidisciplinary neuro-oncology board review for treatment planning.
• Exclude patients with primary intracranial tumors or small cell lung carcinoma receiving prophylactic cranial radiotherapy.

Management

• Classify systemic treatment status at BM diagnosis as first line, continued, switched, no systemic treatment but options available, or no systemic treatment options.
• Consider stereotactic radiotherapy (single fraction, fractionated, staged, or postoperative) or whole brain radiotherapy based on tumor burden and patient factors.
• Decide between immediate radiotherapy, delayed radiotherapy awaiting systemic treatment response, or best supportive care based on clinical parameters and expected intracranial response.

Monitoring & Follow-up

• Assess overall survival from BM diagnosis to death using clinical reports and follow-up.
• Monitor intracranial response to systemic treatments to guide timing of radiotherapy.
• Review multidisciplinary board decisions regularly to adapt treatment plans.

Risks

• Potential variability in intracranial response rates and duration depending on systemic agent and tumor molecular profile.
• Risk of undertreatment if systemic therapy response is overestimated delaying necessary local therapy.
• Risk of overtreatment if immediate radiotherapy is given without considering systemic treatment efficacy.

Patient & Prescribing Data

676 adult patients with brain metastases from breast cancer, NSCLC, melanoma, and other tumors treated between 2018 and 2020

Systemic treatment strategies varied between first line, continuation, switching, or no options; multidisciplinary decisions influenced timing and modality of radiotherapy; survival outcomes correlated with treatment approach and patient characteristics.

Clinical Best Practices

• Integrate molecular profiling of primary tumors to guide targeted systemic therapies for brain metastases.
• Utilize multidisciplinary neuro-oncology boards to individualize treatment decisions balancing systemic and local therapies.
• Stratify patients based on performance status, extracranial disease status, and systemic treatment options to optimize timing of radiotherapy.
• Employ stereotactic radiotherapy modalities tailored to tumor volume and number of lesions.
• Continuously monitor intracranial response to systemic therapies to adjust treatment plans promptly.

References

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13